Updates and news related to prostate cancer:
Research shows a promising new option for men who experience rising PSA after a radical prostatectomy.
Focal therapy using MRI-guided focused ultrasound is safe and effective for men with intermediate-risk prostate cancer who seek to avoid more invasive treatments, according to a study.
In a study, 83% of patients who received focal HIFU for localized prostate cancer remained free from radical therapy at 36 months.
About 60% of men with low-risk prostate cancer now opt for active surveillance.
Uses, benefits and side effects
HERO study in men with advanced prostate cancer based on baseline BMI
Neurovascular bundles are spared if intraoperative pathologic examination of tissue adjacent to the bundles following removal of the prostate shows negative surgical margins.
AstraZeneca and Merck's Lynparza won an FDA go-ahead in prostate cancer this past May.
The combination of two powerful drugs with excellent clinical track records isn’t necessarily a guarantee for success.
German case series suggests it may be feasible